Journals / The Anatolian Journal of Cardiology / 2020 / Cilt: 24 - Sayı: 2

Usefulness of Kawasaki disease risk scoring systems to the Turkish population

Pages
97–106
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It is necessary to determine more specific and sensitive risk scores that increase the risk of IVIG resistance and the development of CAA in Turkey.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Kawasaki disease (KD) is the most common cause of coronary artery aneurysm (CAA) in children.
📊
Key Findings & Data:This study aimed to evaluate the ability of 5 risk scoring systems to predict IVIG resistance and CAA in Turkey patients with KD.Methods: Patients with KD were retrospectively evaluated with clinical, laboratory, and echocardiographic findings.
💡
Conclusion & Impact:It is necessary to determine more specific and sensitive risk scores that increase the risk of IVIG resistance and the development of CAA in Turkey.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Kawasaki disease (KD) is the most common cause of coronary artery aneurysm (CAA) in children. The available risk scores to predict intravenous immunoglobulin (IVIG) resistance and CAA were developed in Asian populations in whom their effectiveness has been proven, but data on non-Asian children are limited. This study aimed to evaluate the ability of 5 risk scoring systems to predict IVIG resistance and CAA in Turkey patients with KD.Methods: Patients with KD were retrospectively evaluated with clinical, laboratory, and echocardiographic findings. Data analyses were performed in 5 scoring systems (Harada, Kobayashi, Egami, Formosa, and Sano).Results: A total of 259 patients (Male:Female, 1.7) were treated for KD in our hospital. The mean age of diagnosis in patients with KD, CAA, and IVIG resistance were 3.31, 2.19, and 2.06, respectively. CAA development and IVIG resistance were seen in 11.6% and 12.3% of cases, respectively. IVIG resistance was detected in 35.6% of patients with CAA. In our study, 5 risk scoring systems were applied to our patients. ROC analysis results were found highest in Kobayashi scoring system for IVIG resistance (AUC, 0.864) and in Harada scoring system for CAA development (AUC, 0.727).Conclusion: Harada score was significant in predicting CAA risk, and Kobayashi score was significant in predicting the risk of developing IVIG resistance. It is necessary to determine more specific and sensitive risk scores that increase the risk of IVIG resistance and the development of CAA in Turkey.

🔖

Cite This Article

ÖZTARHAN, K., VARLI, Y. Z., AYAZ, N. A. (2020). Usefulness of Kawasaki disease risk scoring systems to the Turkish population. The Anatolian Journal of Cardiology, Cilt: 24 - Sayı: 2, 97–106. https://ajindex.com/articles/365170

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967; 16: 178-222
  2. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al.; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017; 135: e927-99
  3. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al.; Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease; Council on Cardiovascular Disease in the Young; American Heart Association; American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110: 2747-71
  4. Moffett BS, Syblik D, Denfield S, Altman C, Tejtel-Sexson K. Epidemiology of immunoglobulin resistant Kawasaki disease: results from a large, national database. Pediatr Cardiol 2015; 36: 374-8
  5. Kobayashi T, Inoue Y, Morikawa A. Risk stratification and prediction of resistance to intravenous immunoglobulin in Kawasaki disease. Nihon Rinsho 2008; 66: 332-7
  6. Rigante D, Andreozzi L, Fastiggi M, Bracci B, Natale MF, Esposito S. Critical Overview of the Risk Scoring Systems to Predict Non- Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome. Int J Mol Sci 2016; 17: 278
  7. Tewelde H, Yoon J, Van Ittersum W, Worley S, Preminger T, Goldfarb J. The Harada score in the US population of children with Kawasaki disease. Hosp Pediatr 2014; 4: 233-8
  8. Skochko SM, Jain S, Sun X, Sivilay N, Kanegaye JT, Pancheri J, et al. Kawasaki disease outcomes and response to therapy in a multiethnic community: a 10-year experience. J Pediatr 2018; 203: 408-15
  9. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 1991; 33: 805-10
  10. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki diseas